Bleeding disorders:
Indications for: CYKLOKAPRON
Short-term use in hemophilia to reduce or prevent hemorrhage, and reduce the need for replacement therapy during and following tooth extraction.
Adults and Children:
Give by IV inj. Max injection rate: 1mL/min. Pre-extraction: 10mg/kg; post-op: 10mg/kg 3–4 times daily for 2–8 days. Renal impairment: serum creatinine 1.36–2.83mg/dL: 10mg/kg twice daily; 2.83–5.66mg/dL: 10mg/kg once daily; >5.66mg/dL: 10mg/kg every 48hrs or 5mg/kg every 24hrs.
CYKLOKAPRON Contraindications:
Subarachnoid hemorrhage. Active intravascular clotting.
CYKLOKAPRON Warnings/Precautions:
For IV use only. Confirm the correct route of administration. Therapy longer than 3 months: do ophthalmologic exam at regular intervals; discontinue if visual changes occur. Risk of seizures esp. during cardiovascular surgery or inadvertent neuraxial administration. Renal impairment: reduce dose. History of thromboembolic disease. Pregnancy. Nursing mothers.
CYKLOKAPRON Classification:
Plasminogen activation inhibitor.
CYKLOKAPRON Interactions:
Avoid concomitant Factor IX complex concentrates, Anti-inhibitor coagulant concentrates, or hormonal contraceptives; increased risk of thrombosis. Do not mix with solutions containing penicillin or with blood products.
Adverse Reactions:
GI upset, allergic dermatitis, giddiness, hypotension, visual abnormalities; thromboembolic events (rare), dizziness, convulsions, anaphylaxis.
Drug Elimination:
After an intravenous dose of 1 g, the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase.
Urinary excretion is the main route of elimination via glomerular filtration. Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug.
Generic Drug Availability:
YES
How Supplied:
Single-dose amps (10mL)—1, 10; single-dose vials (10mL)—10
